Fannie Mae, Freddie Mac shares tumble after conservatorship comments
MIAMI - Longeveron Inc. (NASDAQ:LGVN), a $23 million market cap biotechnology company currently considered undervalued according to InvestingPro analysis, has licensed a U.S. patent for stem cell technology from the University of Miami that could advance treatments for heart diseases, the company announced Monday.
The licensed patent (12,168,028 B2) protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells. These specialized cells can differentiate into human cardiac muscle cells while potentially avoiding the risk of ventricular arrhythmias that has hindered previous stem cell approaches.
"This technology provides a solution to one of the most difficult barriers to the implementation of induced pluripotent stem cells technology in the cardiovascular space," said Joshua Hare, Co-founder, Chief Science Officer, and Chairman at Longeveron. The company maintains a strong liquidity position with a current ratio of 5.6x and holds more cash than debt on its balance sheet, according to InvestingPro data.
The patented technology works by selecting cells destined to become cardiomyocytes while eliminating cells with electrical automaticity found in conduction tissue. This approach allows for new contractile tissue without the risk of causing dangerous heart rhythm abnormalities.
Longeveron, a clinical stage regenerative medicine biotechnology company, believes the technology could be applicable to a broad range of cardiovascular diseases in adults and rare pediatric conditions.
The company’s lead investigational product, laromestrocel (Lomecel-B), is currently being developed for hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
This announcement comes after Longeveron recently received IND approval for pediatric dilated cardiomyopathy, according to the press release statement. While the company shows promising technological advances, InvestingPro data indicates analysts anticipate a sales decline in the current year. Discover more insights and 6 additional ProTips with an InvestingPro subscription, including detailed analysis of the company’s financial health and growth prospects.
In other recent news, Longeveron Inc. has announced several significant developments. The company reported a 30% decline in revenue for the first quarter of 2025 compared to the same period in 2024, with revenues falling to $400,000. The net loss increased to $5 million, up from $4 million in the previous year. Despite these financial challenges, Longeveron received U.S. FDA approval for its Investigational New Drug (IND) application for laromestrocel, a stem cell therapy targeting pediatric dilated cardiomyopathy. This approval allows Longeveron to move directly to a Phase 2 pivotal registration clinical trial expected to start in 2026. Additionally, Longeveron completed enrollment in its Phase 2b trial for Hypoplastic Left Heart Syndrome (HLHS), with top-line results anticipated in the third quarter of 2026. The company appointed Than Powell as Chief Business Officer to lead its business strategy, particularly in its Alzheimer’s disease program and international efforts for the HLHS program. These developments indicate Longeveron’s focus on advancing its clinical trials and potential market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.